Skip to main content

Lobbying activity

Who's lobbying Congress, for whom, and on what, from federal Lobbying Disclosure Act filings. Covers both chambers, synced daily. 19,304 filings

Top spenders & firms Spend by issue

Clear
Q4
MR. LANDON FULMER for KANSAS HOSPITAL ASSOCIATION
4th Quarter (Oct 1 - Dec 31) 2025 · Kansas · House · Senate · $20,000.00 income
Health Issues, Medicare/Medicaid
View →
Q4
MEDSECUREAN.COM for LUPIN PHARMACEUTICALS
4th Quarter (Oct 1 - Dec 31) 2025 · Florida · Senate · $42,000.00 income
Health Issues, Trade (domestic/foreign)
View →
Q4
MEDSECUREAN.COM for INDIAN PHARMACEUTICAL ALLIANCE(FORMERLY INDIAN PHARMACEUTICAL ASSOCIATION)
4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $900,000.00 income
Health Issues, Trade (domestic/foreign)
View →
RR
LIBERTY PARTNERS GROUP, LLC for GENTIVA
1st Quarter (Jan 1 - Mar 31) 2026 · Georgia
Health Issues, Medicare/Medicaid
View →
RR
LIBERTY PARTNERS GROUP, LLC for INTELAS (AQMDS)
1st Quarter (Jan 1 - Mar 31) 2026 · Pennsylvania
Health Issues, Medicare/Medicaid
View →
RR
LIBERTY PARTNERS GROUP, LLC for SODEXO (AQMDS)
1st Quarter (Jan 1 - Mar 31) 2026 · Maryland
Health Issues, Medicare/Medicaid
View →
RR
LIBERTY PARTNERS GROUP, LLC for ANGIOSAFE (CARDIOVASCULAR COALITION)
1st Quarter (Jan 1 - Mar 31) 2026 · California
Health Issues, Medicare/Medicaid
View →
RR
THORN RUN PARTNERS for CITY OF NEW ORLEANS
1st Quarter (Jan 1 - Mar 31) 2025 · Louisiana
Budget/Appropriations, Health Issues
View →
Q4
CHECKMATE GOVERNMENT RELATIONS for REDCAP LLC
4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · $35,000.00 income
Health Issues
View →
RR
MONUMENT ADVOCACY for SOLVENTUM HEALTH INFORMATION SYSTEMS, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · Utah
Health Issues
View →
RR
MONUMENT ADVOCACY for SCHIZOPHRENIA POLICY ACTON NETWORK, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · Virginia
Health Issues
View →
RR
MONUMENT ADVOCACY for NATIONAL COUNCIL FOR PRESCRIPTION DRUG PROGRAMS
1st Quarter (Jan 1 - Mar 31) 2026 · Arizona
Health Issues
View →
RR
MONUMENT ADVOCACY for MCKESSON CORPORATION
1st Quarter (Jan 1 - Mar 31) 2026 · Texas
Health Issues
View →
RR
MONUMENT ADVOCACY for HEALTH INNOVATION ALLIANCE
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia
Health Issues
View →
RR
MONUMENT ADVOCACY for CENCORA
1st Quarter (Jan 1 - Mar 31) 2026 · Pennsylvania
Health Issues
View →
RR
MONUMENT ADVOCACY for COUNCIL FOR AFFORDABLE HEALTH COVERAGE
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia
Health Issues
View →
RR
ALSTON & BIRD LLP for AMPUTEE COALITION
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia
Budget/Appropriations, Health Issues
View →
RR
MONUMENT ADVOCACY for ATHENAHEALTH, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts
Health Issues
View →
RR
YONDR INC for YONDR INC
1st Quarter (Jan 1 - Mar 31) 2026 · California
Arts/Entertainment, Consumer Issues/Safety/Products, Education, Health Issues
View →
RR
HITTLE STRATEGIES, LLC for PARTNERSHIP FOR EMPLOYER SPONSORED COVERAGE
1st Quarter (Jan 1 - Mar 31) 2026 · Virginia
Health Issues
View →
RR
HITTLE STRATEGIES, LLC for NOMI HEALTH, INC.
1st Quarter (Jan 1 - Mar 31) 2026 · Utah
Health Issues
View →
1T
JEFFREY J. KIMBELL & ASSOCIATES, INC. for AXOGEN CORPORATION
1st Quarter (Jan 1 - Mar 31) 2026 · Florida · House · Senate · $15,000.00 income
Health Issues
View →
Q4
CHECKMATE GOVERNMENT RELATIONS for GRAND PHARMACEUTICAL GROUP LTD (FKA EAST OCEAN MEDICAL (HONG KONG) LIMITED)
4th Quarter (Oct 1 - Dec 31) 2025 · $30,000.00 income
Health Issues, Foreign Relations
View →
RR
JEFFREY J. KIMBELL & ASSOCIATES, INC. for ORCHARD THERAPEUTICS NORTH AMERICA
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts
Pharmacy, Medicare/Medicaid, Health Issues
View →
Q4
GREEN MOUNTAIN STRATEGIES LLC DC for ONELEGACY
4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $10,000.00 income
Health Issues
View →
Previous Page 165 of 773 Next

Source: federal Lobbying Disclosure Act filings. A filing's bill references are parsed from its activity descriptions, so a bill page shows the filings that named it.

Report a problem